-
Analyst Opinions
Industrial Robots: Trends and Innovations
Industrial Robots move from automation to autonomy Industrial robotics is entering a new phase of transformation as intelligent, mobile, and humanoid systems reshape automation across sectors. Evolving beyond traditional caged robots, next-generation platforms integrate AI, computer vision, digital twins, and advanced actuation to enable adaptive, flexible, and connected operations. Automotive, electronics, and aerospace remain core adopters, while healthcare, construction, and logistics are emerging growth frontiers. Companies such as BMW, Mercedes-Benz, and Tesla are piloting humanoids for assembly and logistics, ABB,...
-
Sector Analysis
Huntington’s Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7MM and provides an Excel-based forecast model for the Huntington’s Disease market through 2034. The current HD treatments are used to alleviate the symptoms associated with the disease, with all of the approved drugs indicated for the management of chorea associated with HD. VMAT2 inhibitors dominated the HD market in 2024, accounting for 99.8% of sales in the 7MM. The key focus in the pipeline is on developing DMTs for HD, and huntingtin-lowering strategies are key...
-
Thematic Analysis
China's Evolution in Global Drug Development and Clinical Trials: Strategic Intelligence
In 2015, China’s state council launched ‘Opinions on Deepening the Reform of the Review and Approval Processes to Encourage Innovation of Drugs and Medical Devices,’ which was the catalyst of change to implement several regulatory frameworks to encourage domestic innovation, expedite drug approvals, and enhance China’s presence on the global pharmaceutical stage. The US has the largest share of global drugs in development at 40%, China has 20%, and the 5EU (France, Germany, Italy, Spain, and the UK) has 11%...
-
Thematic Analysis
China's Licensing Trends Shaping Global Drug Development: Strategic Intelligence
Over the past five years, China’s biotech sector’s out-licensing deals have increased significantly. Between 2020 and 2024, the compound annual growth rate (CAGR) was approximately 21.7% for licensing agreements, which is a significant increase highlighting the strength of innovative drugs coming from China. This can be attributed to accelerated regulatory reforms, resulting in streamlined drug approvals and extended market exclusivity. Oncology accounted for 59% of these deals and made up 52% of the total deal value during this time period....
-
Sector Analysis
European Association for the Study of Diabetes (EASD): 2025 Annual Meeting Highlights
The European Association for the Study of Diabetes (EASD) is a leading academic, non-profit organization dedicated to advancing research, education, and care in the field of diabetes mellitus. Founded in 1965 and headquartered in Düsseldorf, Germany, EASD brings together scientists, clinicians, nurses, allied health professionals, and students from around the world who are interested in diabetes research and its clinical application. EASD 2025 took place in Vienna, Austria, between 15-19 September 2025. GlobalData's infectious diseases team attended industry-sponsored and scientific sessions...
-
Sector Analysis
Industry Scores a Win as Watered-Down Version of Canada’s IRP Reform Unveiled in Final Guidelines, but Prices Will Nevertheless Decline
Shortly after the release of Canada's long-awaited final guidelines for the implementation of its International Reference Pricing (IRP) system reform, GlobalData reflects on how the final reform compares to the original plans and where the real danger to the pharma industry lies as the new rules take effect.
-
Sector Analysis
Atrial Fibrillation Major Markets Drug Forecast and Market Analysis
The table below presents the key metrics for atrial fibrillation (AF) in the eight major pharmaceutical markets (8MM) covered in this report—the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and Canada—during the forecast period from 2022–32. In 2022, GlobalData estimated that the global AF market reached $14.5 billion across the 8MM. The US makes up the majority of total global sales, contributing $10.7 billion (74%) due to the large prevalent AF population in the US, early adoption...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Basal Cell Carcinoma (Basal Cell Epithelioma) - Global Clinical Trials Review, 2025" provides an overview of Basal Cell Carcinoma (Basal Cell Epithelioma) Clinical trials scenario. This report provides top line data relating to the clinical trials on Basal Cell Carcinoma (Basal Cell Epithelioma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) - Global Clinical Trials Review, 2025" provides an overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by...
-
Product Insights
Herpes Zoster (Shingles): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Herpes Zoster (Shingles) - Global Clinical Trials Review, 2025" provides an overview of Herpes Zoster (Shingles) Clinical trials scenario. This report provides top line data relating to the clinical trials on Herpes Zoster (Shingles). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.